Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TACR1 | P25103 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | TACR2 | P21452 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005239 | 1.00 | TACR3 (0.63) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL16115756 | 0.84 | TACR3 (0.74) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL29967223 | 0.84 | TACR3 (0.74) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL30620753 | 0.82 | TACR3 (0.42) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL30620769 | 0.82 | TACR3 (0.42) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL30627720 | 0.81 | TACR3 (0.67) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL30620768 | 0.81 | TACR3 (0.63) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL29941160 | 0.81 | TACR3 (0.63) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL29967135 | 0.80 | TACR3 (0.55) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL30627826 | 0.79 | TACR3 (0.64) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731974-B2 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | OGEDA SA (BE) | 2023-08-22 | — | — | US | disclosed |
| US-20190092777-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | OGEDA SA (BE) | 2019-03-28 | — | — | US | disclosed |
| US-20180111943-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | OGEDA SA (BE) | 2018-04-26 | — | — | US | disclosed |
| US-9422299-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | EUROSCREEN SA (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20150232471-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | OGEDA SA (BE) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232471-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | GPR3, KCNK3, ACKR3 | TACR3 20/4885KCNH2 77/4885CYP2C9 2409/4885 |
| US-20180111943-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | PKD1, GPR3, FFAR3 | TACR3 104/4885KCNH2 139/4885CYP2C9 1839/4885 |
| US-11731974-B2 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | PKD1, KISS1R, PKD2 | TACR3 98/4885KCNH2 131/4885CYP2C9 1511/4885 |
| US-20190092777-A1 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | PKD1, GPR3, FFAR3 | TACR3 104/4885KCNH2 139/4885CYP2C9 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.